To meet the development needs, Staidson (300204.SZ) plans to introduce investors Yineliyuanli Fund for its subsidiary Beitai.

Staidson (300204.SZ) announced that its subsidiary, Jiangsu Beijetai Biotechnology Co., Ltd. (referred to as "Beijetai"), plans to increase its capital and expand its shares, and transfer its equity by introducing investors Wuxi Jinyi Original Force Equity Investment Partnership Enterprise (Limited Partnership) (referred to as "Jinyi Original Force Fund"). The total capital increase this time is 133 million yuan, of which 5.3333 million yuan is included in the registered capital and 128 million yuan is included in the capital surplus; at the same time, Staidson will transfer the 2.6667 million yuan registered capital of Beijetai it holds to the Jinyi Original Force Fund, with a transfer price of 66.6667 million yuan. Staidson and other shareholders of Beijetai have waived the priority subscription right for this capital increase and the priority right to purchase shares. After the capital increase and equity transfer, the registered capital of Beijetai will increase from 90 million yuan to 95.3333 million yuan, and Staidson's total shareholding in Beijetai will decrease from 100% to 91.6084%. The company will still be the controlling shareholder of Beijetai, and this will not lead to changes in the company's consolidated financial statements. The Jinyi Original Force Fund has invested a total of 200 million yuan in the capital increase and equity transfer of Beijetai, and after the completion of the capital increase and equity transfer, Jinyi Original Force Fund will hold 8 million yuan in registered capital and 8.3916% of the shares in Beijetai. It is reported that the implementation of the above-mentioned matters is based on the development needs of the company, which will help to better promote the ongoing projects.